Literature DB >> 15515006

Fibrotic valvular heart disease is not related to chemical class but to biological function: 5-HT2B receptor activation plays crucial role.

Reinhard Horowski, Sven Jähnichen, Heinz H Pertz.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15515006     DOI: 10.1002/mds.20329

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  6 in total

1.  Ergoline and non-ergoline derivatives in the treatment of Parkinson's disease.

Authors:  Heinz Reichmann; Anja Bilsing; Reinhard Ehret; Wolfgang Greulich; Jörg B Schulz; Andreas Schwartz; Olivier Rascol
Journal:  J Neurol       Date:  2006-08       Impact factor: 4.849

2.  Reversible cardiac valve fibrosis secondary to treatment with high-dose cabergoline for Parkinson's disease.

Authors:  Johannes Levin; Joachim Neudert; Ludwig Zwermann; Michael Näbauer; Kai Bötzel
Journal:  J Neurol       Date:  2011-05-12       Impact factor: 4.849

Review 3.  Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.

Authors:  Jaime Kulisevsky; Javier Pagonabarraga
Journal:  Drug Saf       Date:  2010-02-01       Impact factor: 5.606

Review 4.  Serotonin pharmacology in the gastrointestinal tract: a review.

Authors:  D T Beattie; J A M Smith
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-04-09       Impact factor: 3.000

Review 5.  Dopamine receptors and Parkinson's disease.

Authors:  Shin Hisahara; Shun Shimohama
Journal:  Int J Med Chem       Date:  2011-06-13

Review 6.  Parkinson's disease between internal medicine and neurology.

Authors:  Ilona Csoti; Wolfgang H Jost; Heinz Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2015-08-23       Impact factor: 3.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.